138 Diffusion MRI ADC Mapping of Glioblastoma Edema/Tumor Invasion and Associated Gene Signatures. (August 2015)

• Record Type: Journal Article
• Authors: Zinn, Pascal O.; Hatami, Massumeh; Colen, Rivka R.
• Is Part Of: Clinical neurosurgery. Volume 62(2015)Supplement 1
• Publication Date: 2015-08
• Subjects: Nervous system -- Surgery -- Congresses; Neurosurgery; Nervous system -- Surgery; Neurologie; Congresses; Conference papers and proceedings; 617.48
• DOI: 10.1227/01.neu.0000467100.29806.02
• Languages: English
• ISSNs: 0069-4827

Abstract

Abstract : INTRODUCTION: Diffusion magnetic resonance (dMR) imaging is widely used in clinical practice and captures a distinct molecular/cellular features of tumor tissue. The aim of this study is to correlate pretreatment tumor Apparent Diffusion Coefficient (ADC), measured by dMR imaging with overall survival in patients with glioblastoma and determine its association with gene signatures. METHODS: We retrospectively identified 37 treatment-naïve glioblastoma patients from The Cancer Genome Atlas (TCGA) whom had gene expression profiles and corresponding dMR imaging available in The Cancer Imaging Archive (TCIA). ADC means were measured in edema/tumor invasion of GBM lesions and contralateral normal brain tissue. To normalize ADC values, ADC means of edema/tumor invasion regions were divided by the contralateral ADC means. With the use of the decision tree clustering method, patients were categorized based on normalized ADC mean into high vs low groups. Kaplan-Meier survival analysis was used to determine the difference of overall survival between the 2 groups of patients. Imaging genomic analysis was subsequently performed using GenePattern Comparative Marker Selection module (Broad Institute). To identify the associated gene network, the top 100 most positively and the top 100 most negatively correlated genes in the high group vs the low group were then analyzed with Ingenuity Pathway Analysis. RESULTS: Based on decision tree analysis, the normalized ADC mean cutoff of 19.48 was used to categorize patients in high (n = 6) vs low (n = 31) groups. Kaplan-Meier analysis showed the patients with high normalized ADC mean had significantly ( P = .02) better overall survival than the patients with low normalized ADC mean. Median survival in high and low groups was 747 and 394 days, respectively. There was a significant genomic signature, associated with high vs low groups. The validation of these analyses was done in a separate group of glioblastoma patients. CONCLUSION: We demonstrate that dMR characteristics can identify highly significant survival differences and specific genomic signatures.